**Abstract:** Background and objectives: Sargassum miyabei Yendo, belonging to the family Sargassaceae, has been reported to have various biological effects such as anti-tyrosinase activity and anti-inflammation. However, the anti-obesity effect of *Sargassum miyabei Yendo* has not yet been reported. Materials and Methods: The effects of *Sargassum miyabei Yendo* extract (SME) on 3T3-L1 adipocytes were screened by 3-(4,5)-dimethylthiazo-2-yl-2,5-diphenyltetrazolium bromide (MTT), Oil red O staining, western blot, and Real-time reverse transcription polymerase chain reaction analyses. Results: Here, we show that SME had potent 2,2'-azinobis-3-ethylbezothiazoline-6-sulfonic acid radical decolorization (ABTS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant activity with half maximal inhibitory concentration (IC50) value of 0.2868 ± 0.011 mg/mL and 0.2941 ± 0.014 mg/mL, respectively. In addition, SME significantly suppressed lipid accumulation and differentiation of 3T3-L1 preadipocytes, as shown by Oil Red O staining results. SME attenuated the expression of adipogenic- and lipogenic-related genes such as peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT-enhancer-binding protein alpha (C/EBPα), CCAAT-enhancer-binding protein delta (C/EBPδ), adiponectin, adipose triglyceride lipase (ATGL), fatty acid synthase (FAS), hormone-sensitive lipase (HSL), and lipoprotein lipase (LPL). Conclusions: These findings suggest that SME may have therapeutic implications for developing a new anti-obesity agent.

**Keywords:** *Sargassum miyabei Yendo*; brown algae; 3T3-L1; obesity; lipid accumulation

1. Introduction

Obesity is defined as excessive weight gain characterized by inordinate fat accumulation in the body [1]. It is associated with energy imbalance, which increases adipocyte hyperplasia, causing hypertrophy of white adipose tissue and increased risk of adverse health conditions, including diabetes, hyperlipidemia, hypertension, and cardiovascular disease [2]. Several studies have reported a relationship between obesity and lipid accumulation by evaluating adipocyte differentiation [3]. The preadipocyte 3T3-L1 cell line is a well-established model for the study of adipogenesis inhibition and various stages of obesity [4]. Many studies have investigated the activity of therapeutic drugs.
such as synthetic orlistat (Xenical) and sibutramine (Reductil) using the 3T3-L1 cell line, which has been extensively prescribed to treat obesity. However, these drugs are reported to possess adverse effects, including insomnia, steatorrhea, tension headaches, and excessive thirst [5]. Natural sources are deemed safer and less toxic than synthetic agents in therapeutic approaches [6]. Many investigations are thereby focusing on the development of anti-obesity agents from natural sources.

Recent research has shown that some herbs and their metabolites could exert antioxidant activity to mitigate obesity and obesity-related chronic diseases [7]. For instance, green tea, a popular nutraceutical used as an antioxidant, has been reported to increase metabolic rate and body fat metabolism [8]. Therefore, plants with antioxidant properties, including green tea, have the potential to exert therapeutic properties against obesity.

Sargassum miyabei is a species of brown algae widespread across the coasts of Japan [9] that is reported to inhibit Reactive oxygen species (ROS) generation and tyrosinase activity [10,11]. Previous studies have found that Sargassum miyabei Yendo extract (SME) could induce anti-inflammatory activity through the inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and mitogen-activated kinase (MAPK) activation [12]. However, specific anti-obesity effects of SME have not been reported. The present study investigated the antioxidant activity and effects of Sargassum miyabei Yendo extract (SME) on lipid accumulation during the differentiation of murine preadipocyte 3T3-L1 cells by measuring levels of adipogenic- and lipogenic-related genes.

2. Materials and Methods

2.1. Sample Preparation

Sargassum miyabei extract powder (voucher number; MBRB0038TC9306E1) was obtained from the National Marine Biodiversity Institute of Korea (MABIK). We dissolved 20 mg of Sargassum Miyabei extract powder in 80% ethanol to a final concentration of 20 mg/mL and then filtered the solution through a 0.2 μM pore size syringe filter. The resulting SME was stored at −20 °C before experimentation.

2.2. Chemicals

Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and newborn calf serum (BCS) were purchased from Gibco Life Technologies (Grand Island, NY, USA), Insulin, indomethacin, dexamethasone, 3-isobutyl-1-methylxanthine, and Oil Red O solution were purchased from Sigma-Aldrich (St Louis, MO, USA). Insulin, indomethacin, dexamethasone, 3-isobutyl-1-methylxanthine, and Oil Red O solution were purchased from Sigma-Aldrich (St Louis, MO, USA). Primers were purchased from Macrogen (Seoul, Korea). Anti-C/EBPα antibody and anti-β-actin antibody were purchased from Cell Signaling Technology (Beverly, MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Anti-PPARγ antibody and anti-adiponectin antibody were purchased from Abcam (Cambridge, UK).

2.3. Antioxidant Analysis

2.3.1. 2,2-diphenyl-1-picrylhydrazyl (DPPH)

The antioxidant activity of SME was measured by DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging method [13]. A 100 μL aliquot of SME was mixed with 900 μL DPPH (Sigma-Aldrich Co., St. Louis, MO, USA) solution dissolved in ethanol. The sample was kept in the dark for 30 min, and absorbance was measured by spectrophotometry at 517 nm. DPPH radical scavenging activity was calculated using this formula:

DPPH (%) = (control-absorbance – sample absorbance/blank absorbance) × 100
2.3.2. 2,2′-azinobis-3-ehlbezothiazoline-6-sulfonic Acid Radical Decolorization (ABTS)

ABTS radical solution was prepared by reacting 7 mM ABTS and 2.45 mM aqueous potassium persulfate in 10 mL distilled water for 16 h in the dark at room temperature (RT). A 50 µL aliquot of the sample at different concentrations (0.125, 0.25, 0.5, and 1 mg/mL) was mixed with 950 µL ABTS solution and kept in the dark for 30 min to react. The absorbance was measured by spectrophotometry at 734 nm and calculated as follows:

\[
\text{ABTS scavenging activity (\%) = (control absorbance} - \text{sample absorbance/control absorbance)} \times 100
\]

2.4. Cell Culture

Murine 3T3-L1 preadipocytes cell were purchased from the Korean Cell Line Bank (KCLB, seoul, korea), and 3T3-L1 preadipocytes were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% BCS and 1% penicillin-streptomycin at 37 °C in a humidified 5% CO₂ incubator.

2.5. Adipocyte Differentiation and Drug Treatment

The culture of 3T3-L1 preadipocytes initiated differentiation into mature adipocytes for 2 days after reaching 100% confluence. It was induced by changing the culture medium to DMEM supplemented with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.25 µM dexamethasone (DEX), 167 nM insulin, 100 µM indomethacin and 10% FBS for 2 days. After 2 days, the medium was changed to DMEM containing 10% FBS and 10 µg/mL insulin for 8 days, with changes every 2 days. The SME was then filtered through 0.2 µM-pore size syringe filters and dissolved in differentiation media. 3T3-L1 cells were treated every 2 days with SME at concentrations of 100 or 200 µg/mL during the differentiation process.

2.6. Cell Viability Assay

3T3-L1 preadipocytes were seeded into 96-well plates at a density of 5 × 10⁴ cells per well. After 24 h of incubation, the cells were treated with SME at concentrations of 100 or 200 µg/mL for 48 h. MTT (3-(4,5)-dimethylthiazo-2-yl-2,5-diphenyltetrazolium bromide) solution was added to each well and incubated for 3 h. The reaction products were dissolved in isopropyl alcohol (Duksan Pure Chemicals, Ansan, Korea) for 1 h. The absorbance of the reaction was measured at 595 nm.

2.7. Oil Red O Staining

Oil Red O staining (ORO) was performed as previously described [14,15]. 3T3-L1 preadipocytes were induced to differentiate in SME’s presence or absence (100 or 200 µg/mL). 3T3-L1 preadipocytes and differentiated adipocytes were washed with phosphate-buffered saline (PBS), fixed with 4% formaldehyde for 1 h, and stained with filtered 0.3% Oil Red O solution (Sigma-Aldrich, St. Louis, MO, USA) at RT for 15 min. Then, stained cells were washed three times with distilled water and photographed with a microscope at 400× magnification. The amount of lipid accumulation was quantified by staining the cells with Oil Red O dissolved in isopropyl alcohol and measuring the absorbance at 450 nm.

2.8. Triglyceride Assay

The triglyceride (TG) assay was performed as previously described [16]. Briefly, 3T3-L1 preadipocytes were seeded into 6-well plates with differentiation media and SME (100 and 200 µg/mL) for up to 8 days. After differentiation, cells were lysed in 5% NP-40 lysis buffer, and triglycerides were converted to fatty acids and glycerol with a lipase enzyme. The absorbance of the released glycerol was measured at 570 nm.
2.9. Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR)

After differentiation of 3T3-L1 cells with SME (100 or 200 µg/mL), total RNA was extracted from adipocytes using Trizol reagent. A cDNA library was synthesized with the PrimeScript® RT Reagent Kit (TaKaRa Bio, Kyoto, Japan). mRNA expression levels were quantified by analysis of cDNA implemented by an iCycleriQ™ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) using SYBR Green (TOYOBO, Japan). The conditions of the PCR reaction were as follows: a denaturation cycle at 95 °C for 10 min, followed by 95° C for 15 sec and 60 °C for 10 min. mRNA expression levels were normalized to β-actin, and relative gene expression was expressed as fold change in mRNA expression level. The sequences of PCR primers used in the experiment are shown in Table 1.

| Gene Name   | Accession No. | Forward Primer                  | Reverse Primer                  |
|-------------|---------------|---------------------------------|---------------------------------|
| Adiponectin | NM_009605.4   | GATGGCCTCCTGGAGAGAA             | CGTGGGTGACATCAAAGAGAA           |
| ATGL        | NM_001163689.1| CAAGGCACTAAGAGAGGTACGG          | GACACTGTCATATGGTGACGAC         |
| C/EBPα      | NM_001287523.1| CAAGGCACTAAGAGAGGTACGG          | GACACTGTCATATGGTGACGAC         |
| C/EBPβ      | X62600.1      | TCCACGCTCCTGCCATGTC             | AAGAGTCCTGGTGACGACG           |
| FAS         | AF127033.1    | GGTGCCCTTCCTCCATGTC             | CTAGAAGACTCCAGAGACCTTCC       |
| HSL         | NM_001039507.2| CAGGAGGCACTAGGCGGTGTA           | GGGTCTGGTACCATCTGTC           |
| LPL         | NM_008509.2   | CTGGTGAGGAAATGATG             | TGGGCTGTTGTCTAGGGGTGA         |
| PPARγ       | AB644275.1    | GGAAGACCACTCCGATTCCT             | GTAAATCGAACCACCATTGGGTCA     |
| β-actin     | NM_007393.4   | CGTGGCGTACATCAAAGAGAA           | GACCTGGTGCAATATGGATGA         |

RT-PCR: Reverse Transcription PCR; ATGL: Adipose triglyceride lipase; C/EBPα: CCAAT/enhancer-binding proteins; C/EBPβ: CCAAT/enhancer-binding protein β; FAS: Fatty acid synthase; HSL: Hormone-sensitive lipase; LPL: Lipoprotein lipase; PPARγ: Peroxisome proliferator-activated receptor.

2.10. Western Blot Assay

After 3T3-L1 preadipocytes were differentiated in the absence or presence of SME (100 and 200 µg/mL), cells were lysed with radioimmunoprecipitation assay (RIPA) lysis buffer containing phosphatase inhibitor and protease inhibitor. Total protein (30 µg) content was separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS)-polyacrylamide gel via electrophoresis and transferred to a nitrocellulose membrane. The membranes were blocked with 5% skim milk in PBS for 1 h and incubated with the relevant primary antibody overnight at 4 °C, after which the membranes were washed five times with 1x Tris buffered saline-tween (TBS-T) buffer. The membranes were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h and washed five times with TBS-T buffer. Protein bands were visualized using electrochemiluminescence (ECL) and detected on a Fusion Solo Detector (VilberLourmat, Marne La Vallée, France). The total amount of protein was assessed by evaluating protein bands using Image-J software and normalizing values to β-actin.

2.11. Statistical Analysis

Data are represented as means ± standard error of the mean (SEM) and standard deviation (SD) and were analyzed using one-way analysis of variance (ANOVA). A p-value of less than 0.01 was considered statistically significant.

3. Results

This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation, and the experimental conclusions.

3.1. Antioxidant Activity

We evaluated SME’s antioxidant properties by assessing ABTS radical cation and DPPH radical scavenging activity (Table 2). The half maximal inhibitory concentration (IC50) values of SME for
scavenging ABTS and DPPH were 0.2868 mg/mL and 0.2941 mg/mL, respectively. These results suggested that SME showed potent antioxidant activity in ABTS and DPPH scavenging activity, although the effects were lower than IC50 values of ascorbic acid.

Table 2. Antioxidant activity of SME in ABTS and DPPH assays.

| Assay       | Compound          | IC50 (mg/mL)       |
|-------------|-------------------|--------------------|
| ABTS        | Ascorbic acid     | 0.0622 ± 0.002     |
|             | SME               | 0.2868 ± 0.011     |
| DPPH        | Ascorbic acid     | 0.0678 ± 0.003     |
|             | SME               | 0.2941 ± 0.014     |

SME: Sargassum miyabei Yendo extract; ABTS: 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid; DPPH: 2,2'-diphenyl-1-picrylhydrazyl-hydrate; IC50: half maximal inhibitory concentration.

3.2. Effects of SME on 3T3-L1 Preadipocyte Cell Viability

Before evaluating SME’s effects on 3T3-L1 cells, we first examined whether SME was cytotoxic to 3T3-L1 preadipocytes to determine a suitable experimental concentration. Results showed that SME was not cytotoxic to preadipocytes at a concentration of 200 µg/mL (Figure 1). We thereby used SME at 100 and 200 µg/mL for subsequent experiments.

![Figure 1](image)

Figure 1. Effect of Sargassum miyabei Yendo extract (SME) on the cell viability of 3T3-L1 preadipocytes. Cell viabilities were determined by 3-(4,5)-dimethylthiazolo-2-yl-3,5-diphenyltetrazolium bromide (MTT) assay. 3T3-L1 preadipocytes were treated with SME at 100 or 200 µg/mL for 48 h. Formed formazan was quantified by measuring the absorbance at 595 nm. Each experiment was repeated in triplicate. Bars represent mean ± SD from three independent experiments. Con: positive controls.

3.3. SME Effects on Lipid Accumulation and Triglyceride Composition in 3T3-L1 Adipocytes

We investigated the effects of SME on adipogenesis by measuring intracellular lipid accumulation and triglyceride contents; mature adipocytes are characterized by the presence of lipid droplets, which are not found in preadipocytes. SME significantly inhibited adipocyte differentiation and intracellular lipid accumulation in a dose-dependent manner (Figure 2A,B). Furthermore, SME significantly decreased the intracellular triglyceride contents compared with control cells (Figure 2C). These results indicate that SME could exert potent anti-adipogenic effects as evidenced by decreased intracellular lipid accumulation.
Effects of SME on Adipogenesis-Related Gene Expressions during 3T3-L1 Cell Differentiation

We investigated the molecular mechanisms underlying SME’s anti-adipogenic properties on adipocyte differentiation by examining the expression levels of three adipogenesis-related genes, PPARγ, C/EBPα, and adiponectin. SME treatment was associated with a significant decrease in mRNA expression of PPARγ, C/EBPα, and adiponectin (Figure 3A). Adipocyte differentiation is a complex process accompanied by coordinated changes in the expression of genes [17]. C/EBPδ is a critical determinant for the early stage of adipocyte differentiation and later activates the expression of key adipogenic regulators such as PPARγ and C/EBPα [18,19]. Therefore, we investigated SME’s effect on the mRNA expression level of the early adipogenic transcription factor C/EBPδ at an early time point of differentiation. We observed that SME treatment significantly decreased the mRNA expression of C/EBPδ in a concentration-dependent manner (Figure 3B). Protein expression levels of PPARγ, C/EBPα, and adiponectin were also decreased in a dose-dependent manner, concomitant with mRNA expression patterns (Figure 3C,D). These results suggest that SME inhibited adipogenesis by downregulating the PPARγ signaling pathway, and the inhibitory effect may also begin in the early stage of adipocyte differentiation.
Figure 3. Effect of SME on adipogenesis-related gene expressions in 3T3-L1 adipocytes. 3T3-L1 preadipocytes were cultured in differentiation medium in the presence or absence of SME at 100 or 200 µg/mL during differentiation for 8 days. RNA and proteins were isolated from the adipocytes following differentiation. (A) The relative mRNA expression levels of proliferator-activated receptor-γ (PPARγ), CCAAT/enhancer-binding protein α (C/EBPα), and adiponectin were assessed by real-time PCR. (B) 3T3-L1 adipocyte cells were cultured in a differentiation medium with SME at the indicated concentrations for a day. After treatment, the related mRNA expression levels of CCAAT-enhancer-binding protein delta (C/EBPδ) were determined by real-time PCR. (C) Representative images of Western blot results. (D) Quantification of protein expression levels. Each experiment was repeated in triplicate. Bars represent mean ± SD. *p < 0.05 and **p < 0.01 compared to control group.

3.5. Effects of SME on Lipogenic-Related Gene Expressions on 3T3-L1 Adipocytes

To elucidate the molecular mechanisms involved in suppressing intracellular lipid accumulation in SME-treated 3T3-L1 adipocytes, we explored the effect of SME on the mRNA expression of lipogenic-related genes, including adipose triglyceride lipase (ATGL), fatty acid synthase (FAS), hormone-sensitive lipase (HSL), and lipoprotein lipase (LPL). We found that SME treatment significantly decreased the mRNA expression levels of ATGL, fatty acid synthase (FAS), hormone-sensitive lipase (HSL), and lipoprotein lipase (LPL) in a dose-dependent manner (Figure 4). These results suggest that SME inhibited lipid biosynthesis induction in 3T3-L1 by regulating the expression of the primary lipogenic-related genes.
We also demonstrated that SME treatment was associated with significant inhibition of 3T3-L1 cell differentiation, as evidenced by a visible reduction in lipid accumulation. Our finding revealed that SME inhibited adipogenesis by mediating the downregulation of the expression of adipogenic- and differentiation-related genes. These results imply that SME suppressed adipogenesis and lipid accumulation by regulating the complex transcriptional cascade, which is related to several stages of differentiation on 3T3-L1 adipocytes. Our findings suggest SME as a promising natural source for treating obesity. To the best of our knowledge, these results represent the first evidence of SME’s anti-adipogenic effects on 3T3-L1 adipocytes. However, further research to elucidate this capacity and its underlying therapeutic properties in an obese animal model is warranted.

5. Conclusions

We found that SME inhibited intracellular lipid accumulation and adipocyte differentiation in 3T3-L1 cells without cytotoxicity. Multiple studies have reported that adipogenesis-related genes’ expression was significantly elevated in murine models of obesity [24]. In 3T3-L1 adipocytes, the PPARγ signaling pathway has been identified to facilitate cell enlargement and intracellular triglyceride accumulation [25]. We demonstrated that SME treatment significantly attenuated the expression of PPARγ, C/EBPα, C/EBPδ, and adiponectin compared to that in control cells. In addition, we showed that SME treatment regulated the mRNA expression of lipogenic-related genes. These results imply that SME suppressed adipogenesis and lipid accumulation by regulating the complex transcriptional cascade, which is related to several stages of differentiation on 3T3-L1 adipocytes. Our findings suggest SME as a promising natural source for treating obesity. To the best of our knowledge, these results represent the first evidence of SME’s anti-obesity properties could be associated with carotenoid components with antioxidant function present in the extract [23]. However, it should be noted that direct evidence concerning whether the effects of SME were associated with major carotenoids was not assessed in this study.

4. Discussion

SME is known to contain various carotenoids, important dietary nutrients with potential antioxidant activity, such as neoxanthin, fucoxanthin, and fucoxanthinol [20]. Studies have recently demonstrated that dietary supplements with radical scavenging activity could reduce body weight and amelioration of obesity-related disorders [21,22]. Many studies have also suggested that oxidative stress may be an important link between obesity and obesity-related diseases [13]. In this study, SME presented significant antioxidant activity in ABTS and DPPH assays, implying that SME’s anti-obesity properties could be associated with carotenoid components with antioxidant function present in the extract [23]. However, it should be noted that direct evidence concerning whether the effects of SME were associated with major carotenoids was not assessed in this study.

In the present study, we found that SME inhibited intracellular lipid accumulation and adipocyte differentiation in 3T3-L1 cells without cytotoxicity. Multiple studies have reported that adipogenesis-related genes’ expression was significantly elevated in murine models of obesity [24]. In 3T3-L1 adipocytes, the PPARγ signaling pathway has been identified to facilitate cell enlargement and intracellular triglyceride accumulation [25]. We demonstrated that SME treatment significantly attenuated the expression of PPARγ, C/EBPα, C/EBPδ, and adiponectin compared to that in control cells. In addition, we showed that SME treatment regulated the mRNA expression of lipogenic-related genes. These results imply that SME suppressed adipogenesis and lipid accumulation by regulating the complex transcriptional cascade, which is related to several stages of differentiation on 3T3-L1 adipocytes. Our findings suggest SME as a promising natural source for treating obesity. To the best of our knowledge, these results represent the first evidence of SME’s anti-obesity effects on 3T3-L1 adipocytes. However, further research to elucidate this capacity and its underlying therapeutic properties in an obese animal model is warranted.
SME inhibited adipogenesis by mediating the downregulation of the expression of adipogenic- and lipogenic-related genes suggesting that SME may be a promising natural source for the treatment of obesity.

**Author Contributions:** Conceptualization, D.S.K., S.G.L., and J.-O.N.; investigation, D.S.K., S.G.L., and M.K.; methodology, T.O.C.; resources, D.H. and S.K.J.; writing—original draft preparation, D.S.K. and S.G.L.; writing—review and editing, J.-O.N.; project administration, J.-O.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Deurenberg, P.; Yap, M. The assessment of obesity: Methods for measuring body fat and global prevalence of obesity. *Baillieres Best Pract. Res. Clin. Endocrinol. Metab.* 1999, 13, 1–11. [CrossRef] [PubMed]

2. Bluher, M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. *Best Pract. Res. Clin. Endocrinol. Metab.* 2013, 27, 163–177. [CrossRef] [PubMed]

3. Ruiz-Ojeda, F.J.; Ruperez, A.I.; Gomez-Llorente, C.; Gil, A.; Aguilera, C.M. Cell Models and Their Application for Studying Adipogenic Differentiation in Relation to Obesity: A Review. *Int. J. Mol. Sci.* 2016, 17, 1040. [CrossRef] [PubMed]

4. Armani, A.; Mammi, C.; Marzolla, V.; Calanchini, M.; Antelmi, A.; Rosano, G.M.; Fabbri, A.; Caprio, M. Cellular models for understanding adipogenesis, adipose dysfunction, and obesity. *J. Cell Biochem.* 2010, 110, 564–572. [CrossRef]

5. Padwal, R.S.; Majumdar, S.R. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. *Lancet* 2007, 369, 71–77. [CrossRef]

6. Mohamed, G.A.; Ibrahim, S.R.M.; Elkhayat, E.S.; El Dine, R.S. Natural anti-obesity agents. *Bull. Fac. Pharm. Cairo Univ.* 2014, 52, 269–284. [CrossRef]

7. Meydani, M.; Hasan, S.T. Dietary polyphenols and obesity. *Nutrients* 2010, 2, 737–751. [CrossRef]

8. Bahmani, M.; Eftekhari, Z.; Saki, K.; Fazeli-Moghadam, E.; Jelodari, M.; Rafieian-Kopaei, M. Obesity phytotherapy: Review of native herbs used in traditional medicine for obesity. *J. Evid. Based Complement. Altern. Med.* 2016, 21, 228–234. [CrossRef]

9. Umezaki, I. Ecological studies of Sargassum miyabei YENDO in Maizuru Bay, Japan Sea. *Nippon Suisan Gakkaishi* 1983, 49, 1825–1834. [CrossRef]

10. Kang, H.S.; Chung, H.Y.; Kim, J.Y.; Son, B.W.; Jung, H.A.; Choi, J.S. Inhibitory phlorotannins from the edible brown alga Ecklonia stolonifera on total reactive oxygen species (ROS) generation. *Arch. Pharm. Res.* 2004, 27, 194–198. [CrossRef]

11. Kang, H.S.; Kim, H.R.; Byun, D.S.; Son, B.W.; Nam, T.J.; Choi, J.S. Tyrosinase inhibitors isolated from the edible brown alga Ecklonia stolonifera. *Arch. Pharm. Res.* 2004, 27, 1226–1232. [CrossRef] [PubMed]

12. Kim, M.-J.; Bae, N.-Y.; Kim, K.-B.-W.-R.; Park, S.-H.; Jang, M.-R.; Im, M.-H.; Ahn, D.H. Anti-Inflammatory Activity of Ethanol Extract of Sargassum miyabei Yendo via Inhibition of NF-κB and MAPK Activation. *Microbiol. Biotechnol. Lett.* 2016, 44, 442–451. [CrossRef]

13. Blois, M.S. Antioxidant Determinations by the Use of a Stable Free Radical. *Nature* 1958, 181, 1199–1200. [CrossRef]

14. Lee, S.G.; Lee, Y.J.; Jang, M.-H.; Kwon, T.R.; Nam, J.-O. Panax ginseng leaf extracts exert anti-obesity effects in high-fat diet-induced obese rats. *Nutrients* 2017, 9, 999. [CrossRef]

15. Lee, S.G.; Chae, J.; Kim, J.S.; Min, K.; Kwon, T.K.; Nam, J.-O. Jaceosidin Inhibits Adipogenesis in 3T3-L1 Adipocytes through the PPARγ Pathway. *Nat. Prod. Commun.* 2018, 13, 1934578X1803101014. [CrossRef]

16. Lee, S.G.; Kim, J.S.; Min, K.; Kwon, T.K.; Nam, J.-O. Hispidulin inhibits adipogenesis in 3T3-L1 adipocytes through PPARγ pathway. *Chem. Biol. Interact.* 2018, 293, 89–93. [CrossRef]

17. Cho, H.J.; Park, J.; Lee, H.W.; Lee, Y.S.; Kim, J.B. Regulation of adipocyte differentiation and insulin action with rapamycin. *Biochem. Biophys. Res. Commun.* 2004, 321, 942–948. [CrossRef]

18. Lee, S.G.; Taeg, K.K.; Nam, J.O. Silibinin Inhibits Adipogenesis and Induces Apoptosis in 3T3-L1 Adipocytes. *Microbiol. Biotechnol. Lett.* 2017, 45, 27–34. [CrossRef]
19. Hishida, T.; Nishizuka, M.; Osada, S.; Imagawa, M. The role of C/EBPδ in the early stages of adipogenesis. *Biochimie* 2009, 91, 654–657. [CrossRef]

20. Tabakaeva, O.V.; Tabakaev, A.V. Carotenoid Profile and Antiradical Properties of Brown Seaweed Sargassum miyabei Extracts. *Chem. Nat. Compd.* 2019, 55, 364–366. [CrossRef]

21. Abdali, D.; Samson, S.E.; Grover, A.K. How effective are antioxidant supplements in obesity and diabetes? *Med. Princ. Pract.* 2015, 24, 201–215. [CrossRef] [PubMed]

22. Kim, M.J.; Park, M.; Jeong, M.K.; Yeo, J.; Cho, W.I.; Chang, P.S.; Chung, J.H.; Lee, J. Radical scavenging activity and anti-obesity effects in 3T3-L1 preadipocyte differentiation of Ssuk (Artemisia princeps Pamp.) extract. *Food Sci. Biotechnol.* 2010, 19, 535–540. [CrossRef]

23. Miyashita, K. Function of marine carotenoids. In *Food Factors for Health Promotion*; Karger Publishers: Basel, Switzerland, 2009; Volume 61, pp. 136–146.

24. Tung, Y.C.; Hsieh, P.H.; Pan, M.H.; Ho, C.T. Cellular models for the evaluation of the antiobesity effect of selected phytochemicals from food and herbs. *J. Food Drug. Anal.* 2017, 25, 100–110. [CrossRef] [PubMed]

25. Farmer, S.R. Regulation of PPARgamma activity during adipogenesis. *Int. J. Obes. (Lond.)* 2005, 29 (Suppl. 1), S13–S16. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).